System Labs Review – Peptides, and the Regulatory Ground They Stand On

System Labs is a cash-pay telehealth platform selling peptides and longevity treatments — sermorelin, NAD+, glutathione, MIC+B12, GHK-Cu and compounded GLP-1/GIP — with clinician oversight and prices published openly on its site. The pricing transparency is real and we will credit it. The harder question is what regulatory ground several of these products are standing on, and that is not something a buyer can see from a website.

What It Sells, and What It Costs

Cash-pay, no insurance, with per-treatment prices published rather than hidden behind an intake questionnaire. That last point is worth more than it sounds. A large share of the telehealth services on this site make you complete a medical intake before they will show you a number, and we mark them down for it every time. System Labs does not, and it should get credit for that.

The Compounded GLP-1/GIP Question

“GLP-1/GIP” describes a dual agonist — the mechanism of tirzepatide. So the specific question is what molecule is being compounded and on what basis, now that being a cheaper copy of an available brand product is no longer a permitted reason to compound one.

The narrow route that remains is genuine patient-specific compounding for a documented clinical need — a dose that is not commercially manufactured, or an allergy to an inactive ingredient in the approved product. That is a real thing and it does apply to some patients. What it is not is a general-purpose discount channel.

Watch for the workaround, because it is common: adding an ingredient such as B12 to semaglutide and presenting the result as a distinct formulation rather than a copy. The FDA has specifically criticised that practice. Given that System Labs also sells B12 injections, it is a fair question to put directly. Our compounded versus brand-name guide sets out the full position, and the provider comparison covers programs whose GLP-1 offering is their main business rather than one line among many.

Peptides Are in Regulatory Flux

In late 2023 the FDA placed a set of popular peptides in Category 2 — “substances with safety concerns” — which bars compounding pharmacies from preparing them for human use under section 503A. The list included BPC-157, thymosin beta-4, AOD-9604, GHK-Cu, ipamorelin, kisspeptin-10, selank and semax.

The agency gave three reasons: potential immunogenicity, impurities arising from bulk peptide manufacture, and insufficient human safety data. In September 2024 it removed five substances from the list, and more recently HHS has signalled that a majority of the restricted peptides are expected to move back to Category 1.

GHK-Cu is the one to raise here, since System Labs sells a GHK-Cu cream. There is a genuine distinction between a topical cosmetic containing GHK-Cu, which is commonplace and unremarkable, and a compounded drug preparation, which is what the Category 2 listing addresses. We could not establish which this product is. That is exactly the question to ask, and a straight answer to it tells you a lot about the operation.

MIC+B12 Is the Weak Link

The pitch is that these compounds are “lipotropic” and help mobilise fat. The individual substances do have roles in fat metabolism, which is where the story comes from. What is missing is any decent trial showing that injecting them causes people to lose weight.

B12 is worth separating out, because it is the part with a real answer. If you are B12 deficient, repletion genuinely matters and can improve fatigue. If you are not deficient, extra B12 does nothing for your energy or your weight — you excrete it. The test that establishes which applies to you costs less than a month of injections. Ask for the blood result rather than the subscription.

There is also a specific reason B12 deficiency matters to this audience: it is genuinely more common after bariatric surgery and with long-term metformin use, both of which are frequent in people managing weight. That is an argument for testing, not for an untested monthly injection.

NAD+, Glutathione and Sermorelin

NAD+ at $149 injected or $119 as a nasal spray is the flagship longevity product, and the human evidence for the benefits implied is thin. NAD+ levels do decline with age, which is the real observation the category is built on. What has not been demonstrated is that raising them by injection produces the energy, cognition or longevity outcomes buyers expect. Bioavailability is also a genuine question for a molecule of that size, and the nasal spray route has less supporting data than the injection, not more.

Glutathione at $149 has the same shape of problem. It is an important endogenous antioxidant, it is poorly absorbed when taken directly, and the marketed benefits are not established in controlled human research. The FDA has separately warned about injectable glutathione products marketed for skin lightening.

Sermorelin is the most defensible item on the list, and we will say so. It is a growth hormone releasing hormone analogue that was once an approved product, withdrawn for commercial rather than safety reasons, and it remains compoundable. It works by stimulating your own pituitary rather than injecting growth hormone directly, which is a meaningfully safer mechanism.

That said: growth hormone secretagogues are not approved for anti-ageing or body composition in healthy adults, they raise IGF-1, and long-term consequences of doing that electively are not well characterised. The oral compounded version at $159 raises a further question, since peptides are generally poorly absorbed orally — ask what the absorption data for that specific preparation is.

Price the Second Month, Not the First

First-month discounts run 40 to 50 percent across most treatments. Sermorelin at $89 becomes $179. NAD+ injection at $79 becomes $149. The nasal spray at $59 becomes $119 — slightly more than double.

This is standard subscription practice rather than anything underhand, and the real prices are published, which is the important part. But these are treatments sold on the premise of long-term use, so the ongoing rate is the actual price. Someone on sermorelin and NAD+ together is at $328 a month after the introductory period — around $3,900 a year, cash, for two products whose evidence base we have just described.

Pros and Cons

Questions to Ask Before You Sign Up

We would not tell a reader that peptide therapy is categorically wrong. Sermorelin has a coherent mechanism, clinician oversight is better than the grey-market alternative of ordering “research chemicals” online, and some people will pursue this regardless of what a review says. If that is you, the useful thing is knowing what to ask.

• For the GLP-1/GIP product: which molecule, and on what lawful basis is it being compounded now that the shortages are resolved?
• Is anything added to it, and if so, why?
• Is the GHK-Cu product a cosmetic topical or a compounded drug preparation?
• Which pharmacy compounds each product, is it 503A or 503B, and can I see potency testing for my batch?
• What blood work is done before starting, and will you test B12 before selling me B12?
• What is the ongoing monthly price after the first-month discount, and what are the cancellation terms?

Skip it if what you actually want is weight loss. MIC+B12 will not deliver it, and if a GLP-1 is appropriate for you then a program built around that — with the approved product where possible — is the better route. Do not start growth hormone secretagogues without discussing your history, particularly any cancer history, with a clinician who is not selling them to you.

Limitations of This Review

Based on published pricing and independent coverage checked on 7 August 2026. Prices are as reported and may have changed. We could not establish which pharmacies System Labs uses, whether they are 503A or 503B, what the compounded GLP-1/GIP product actually contains or what it costs, whether the GHK-Cu product is a cosmetic or a compounded drug, what blood work is required, state availability, cancellation terms, or independent review scores. The regulatory position on peptide compounding has changed more than once and may have moved again since this date — treat the description here as of the date checked rather than as current legal advice. Statements about evidence come from published research, not from System Labs. Nothing here is medical advice.

Frequently Asked Questions

Verdict

The pricing transparency deserves the credit we have given it. Publishing what things cost, without making you complete a medical intake first, is a standard most of this industry fails.

But the thing worth taking from this page is the timing. The compounded GLP-1 boom rested on a drug shortage, and that shortage is over — which means any program still selling compounded GLP-1s owes you an explanation of what changed and why theirs is still appropriate. Ask it. A clear answer is reassuring, and a vague one is the answer.